Pliant Therapeutics Financials
| PLRX Stock | USD 15.20 0.53 3.61% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.06 | 17.722 |
|
|
The essential information of the day-to-day investment outlook for Pliant Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Pliant Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Pliant Therapeutics.
Net Income |
|
Pliant | Select Account or Indicator |
Understanding current and past Pliant Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Pliant Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Pliant Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Pliant Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pliant Therapeutics. Check Pliant Therapeutics' Beneish M Score to see the likelihood of Pliant Therapeutics' management manipulating its earnings.
Pliant Therapeutics Stock Summary
Pliant Therapeutics competes with KBC Groep, Pfizer, JPMorgan Chase, Davis Select, and Frontline. Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. Pliant Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US7291391057 |
| CUSIP | 729139105 |
| Location | California; U.S.A |
| Business Address | 260 Littlefield Avenue, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | pliantrx.com |
| Phone | 650 481 6770 |
| Currency | USD - US Dollar |
Pliant Therapeutics Key Financial Ratios
| Return On Equity | -0.4 | ||||
| Price To Sales | 3,050 X | ||||
| Revenue | 1.58 M | ||||
| Gross Profit | 9.69 M | ||||
| EBITDA | (182.3 M) |
Pliant Therapeutics Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 119.1M | 295.5M | 221.2M | 350.6M | 512.2M | 537.8M | |
| Net Tangible Assets | (76.3M) | 283.1M | 199.1M | 313.3M | 360.3M | 378.4M | |
| Retained Earnings | (76.3M) | (117.8M) | (215.1M) | (338.4M) | (499.7M) | (474.8M) | |
| Accounts Payable | 1.3M | 2.0M | 3.0M | 1.6M | 4.5M | 2.6M | |
| Cash | 85.8M | 50.9M | 51.7M | 33.7M | 63.2M | 55.1M | |
| Net Receivables | 7.4M | 9.4M | 2.1M | 2.1M | 3.0M | 3.9M | |
| Total Liab | 119.5M | 12.5M | 22.2M | 37.3M | 38.6M | 34.4M | |
| Total Current Assets | 111.9M | 290.8M | 209.4M | 340.3M | 505.5M | 530.8M | |
| Other Current Liab | 6.9M | 9.6M | 12.0M | 19.9M | 22.7M | 13.5M | |
| Net Debt | (85.4M) | (50.6M) | (44.5M) | (17.9M) | (51.9M) | (54.5M) | |
| Other Assets | 3.1M | 451K | 838K | 394K | 1.0 | 0.95 | |
| Other Current Assets | 1.7M | 4.5M | 6.8M | 7.1M | 8.3M | 5.2M | |
| Net Invested Capital | (76.3M) | 283.1M | 199.1M | 323.3M | 483.6M | 507.8M | |
| Net Working Capital | 103.7M | 279.2M | 192.6M | 316.4M | 477.0M | 261.3M |
Pliant Therapeutics Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Pliant Therapeutics. It measures of how well Pliant is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Pliant Therapeutics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Pliant had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Pliant Therapeutics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 24.9M | (34.9M) | 783K | (18.0M) | 29.5M | 31.0M | |
| Depreciation | 1.1M | 1.3M | 1.5M | 1.8M | 1.8M | 1.3M | |
| Capital Expenditures | 964K | 1.5M | 2.0M | 1.8M | 921K | 1.2M | |
| Net Income | (631K) | (41.5M) | (97.3M) | (123.3M) | (161.3M) | (153.3M) | |
| End Period Cash Flow | 85.8M | 50.9M | 51.7M | 33.7M | 63.2M | 55.1M | |
| Change To Netincome | 1.8M | 4.2M | 10.4M | 22.6M | 26.0M | 27.3M | |
| Free Cash Flow | (3.7M) | (38.8M) | (77.4M) | (96.4M) | (117.3M) | (111.4M) |
Pliant Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Pliant Therapeutics's current stock value. Our valuation model uses many indicators to compare Pliant Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pliant Therapeutics competition to find correlations between indicators driving Pliant Therapeutics's intrinsic value. More Info.Pliant Therapeutics is regarded fourth in return on equity category among its peers. It also is regarded fourth in return on asset category among its peers . At this time, Pliant Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pliant Therapeutics' earnings, one of the primary drivers of an investment's value.Pliant Therapeutics Systematic Risk
Pliant Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Pliant Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Pliant Therapeutics correlated with the market. If Beta is less than 0 Pliant Therapeutics generally moves in the opposite direction as compared to the market. If Pliant Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Pliant Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Pliant Therapeutics is generally in the same direction as the market. If Beta > 1 Pliant Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Pliant Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Pliant Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Pliant Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Pliant Therapeutics October 19, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Pliant Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Pliant Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Pliant Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Pliant Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Pliant Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.64 | |||
| Information Ratio | 0.072 | |||
| Maximum Drawdown | 20.65 | |||
| Value At Risk | (5.55) | |||
| Potential Upside | 5.58 |
Additional Tools for Pliant Stock Analysis
When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.